Skip to content
DraconiticResearch
Search Sources API
186,546 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BYFrontiers in oncology

Genesis—progression of early jaw osteoradionecrosis in head and neck cancer survivors: dynamics of independent but interconnected factors

  1. 1Département d’Oncologie-Radiothérapie, Assistance Publique des Hôpitaux de Paris (APHP), Hôpital Saint-Louis , ,

Abstract

Purpose: Long-term head and neck cancer survivors are few, but always exposed to a risk of mandibular osteoradionecrosis (ORN) despite the use of appropriate dose-volume constraints in today’s radiotherapy. Here, ORN development is approached from another look, in an attempt to explain its complexity.

Definitions: Early ORN is best defined by length of the mucosal defect (<2 teeth long) and radiological assessment of the depth of areas of bone resorption (lysis below the level of the inferior alveolar canal) in the radiotherapy volume. Technical improvements have greatly reduced the incidence of ORN, but a lifelong risk remains and requires long-term follow-up.

Causal factors: Pathogenic hypotheses have evolved over time from the “radiation-trauma-infection” triad to the 3H theory of “hypoxia-hypocellularity-hypovascularity”, and then radiation-induced fibro-atrophy of the bone. ORN is a dynamic process combining interacting causal factors that worsen each other over time: (a) radiation-induced fibro-atrophy of the bone and its related radiotherapy technical parameters; (b) periodontal disease/dental trauma and their related questions on optimal timing of pre- or post-radiotherapy extractions and how many teeth; (c) infection/oral microbiota and their related mechanically inaccessible bone sequestra (residual bacteria); (d) vascular factors from capillary network destruction to artery stenosis of irradiated branches and the carotid trunk.

Conclusion: Symptomatic medical care focusing on comorbidity parameters and devitalized tissue removal is not sufficient to protect patients against ORN. These new insights should help to treat early ORN through concomitant control of these causal factors and best dental care.

Related

  1. Alternative lengthening of telomeres and CINSARC are interconnected toward non-translocation-related sarcomas progression
    Gaëlle Pérot, Clémence Guerriau, Natacha Roussel +6
    BMC CancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedPhysiologyPMC
  2. Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis
    Leonardo Palazzo, Ferdinando Clarelli, Michele Surano +6
    European journal of neurologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Neighborhood disadvantages and longitudinal progression of multimorbidity among adult survivors of childhood cancer: a single-center St. Jude Lifetime Cohort Study in the U.S.
    Jaesung Choi, Madeline R. Horan, Sedigheh Mirzaei +13
    eClinicalMedicinePeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMC
  4. A High Level of Calculated Small Dense Low-Density Lipoprotein Cholesterol Is an Independent Risk Factor for the Progression of Renal Impairment
    Hiroki Aida, Marenao Tanaka, Tatsuya Sato +11
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
  5. A 2-year multimodal prospective cohort study to predict sustained progression independent of relapse activity in multiple sclerosis
    Luis Rafael Solís-Tarazona, Salma Reddam, Ana Merchán-Cabanillas +3
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMCPMC
BibTeX
@article{delanian2026genesisprogression,
  title = {{Genesis—progression of early jaw osteoradionecrosis in head and neck cancer survivors: dynamics of independent but interconnected factors}},
  author = {Sylvie E. Delanian},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1941783},
  url = {https://europepmc.org/article/PMC/PMC13691543},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Genesis—progression of early jaw osteoradionecrosis in head and neck cancer survivors: dynamics of independent but interconnected factors
AU  - Sylvie E. Delanian
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1941783
UR  - https://europepmc.org/article/PMC/PMC13691543
AB  - Purpose: Long-term head and neck cancer survivors are few, but always exposed to a risk of mandibular osteoradionecrosis (ORN) despite the use of appropriate dose-volume constraints in today’s radiotherapy. Here, ORN development is approached from another look, in an attempt to explain its complexity.  Definitions: Early ORN is best defined by length of the mucosal defect (<2 teeth long) and radiological assessment of the depth of areas of bone resorption (lysis below the level of the inferior alveolar canal) in the radiotherapy volume. Technical improvements have greatly reduced the incidence of ORN, but a lifelong risk remains and requires long-term follow-up.  Causal factors: Pathogenic hypotheses have evolved over time from the “radiation-trauma-infection” triad to the 3H theory of “hypoxia-hypocellularity-hypovascularity”, and then radiation-induced fibro-atrophy of the bone. ORN is a dynamic process combining interacting causal factors that worsen each other over time: (a) radiation-induced fibro-atrophy of the bone and its related radiotherapy technical parameters; (b) periodontal disease/dental trauma and their related questions on optimal timing of pre- or post-radiotherapy extractions and how many teeth; (c) infection/oral microbiota and their related mechanically inaccessible bone sequestra (residual bacteria); (d) vascular factors from capillary network destruction to artery stenosis of irradiated branches and the carotid trunk.  Conclusion: Symptomatic medical care focusing on comorbidity parameters and devitalized tissue removal is not sufficient to protect patients against ORN. These new insights should help to treat early ORN through concomitant control of these causal factors and best dental care.
SN  - 2234-943X
ER  -